Combination of triazine derivatives and insulin secretion stimulators

A pharmaceutical composition comprising, as active principle:

• i) an insulin secretion stimulator that is a glucagon receptor antagonist, an incretin hormone, DPP-IV inhibitor, a sulfonylurea or a glinide, and, 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine, or a tautomer, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.